US › Healthcare

CG Oncology, Inc. Common stock (CGON)

US · Healthcare · Biotechnology

$71.40+3.25%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$1.1M
Revenue YoY
+1982.7%
Net profit
$-60.2M
Profit YoY
-74.7%
EPS
$-0.71
EPS estimate
$-0.58
Net margin
-5,558.8%

EPS came in at -0.71 against a street estimate of -0.58 — a miss of 22.4%.

Key statistics

Market cap
$6.28B
Forward P/E
0.0
P/B
5.75
Book value
$12.40
EPS (TTM)
$-2.34
52-week high
$77.00
52-week low
$23.65
50-day MA
$66.02
200-day MA
$56.79
Beta
0.22

Analyst view

Analysts rate CG Oncology, Inc. Common stock a buy (9 buy, 1 hold, 0 sell out of 10) with an average price target of $90.69.

Shareholding

Insiders
0.23%
Institutions
109.52%

Largest institutional holders

FundStake
RTW INVESTMENTS, LLC7.92%
T. Rowe Price Investment Management,Inc.7.62%
Decheng Capital LLC7.22%
Wellington Management Company LLP6.09%
BlackRock Inc5.74%
FMR Inc4.27%
TCG Crossover Management, LLC4.16%
T. Rowe Price Associates, Inc.4.14%

Recent filings & reports

DocumentDate
Shareholder vote results · Q2 20262026-06-08
Board / officer change · Q2 20262026-05-26
Quarterly report · Q1 20262026-05-08
Results announced · Q2 20262026-05-08
Proxy statement · Q2 20262026-04-24
Board / officer change · Q2 20262026-04-13
Annual report FY20252026-02-27
Quarterly report · Q3 20252025-11-14

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for CG Oncology, Inc. Common stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.